[go: up one dir, main page]

NI201200183A - Una combinación antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino - Google Patents

Una combinación antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino

Info

Publication number
NI201200183A
NI201200183A NI201200183A NI201200183A NI201200183A NI 201200183 A NI201200183 A NI 201200183A NI 201200183 A NI201200183 A NI 201200183A NI 201200183 A NI201200183 A NI 201200183A NI 201200183 A NI201200183 A NI 201200183A
Authority
NI
Nicaragua
Prior art keywords
derivative
ombrabulin
combination including
platinum
taxane
Prior art date
Application number
NI201200183A
Other languages
English (en)
Inventor
Cohen Patrick
Corina Oprea Ileana
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10305653A external-priority patent/EP2397135A1/en
Priority claimed from EP10306256A external-priority patent/EP2481404A1/en
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of NI201200183A publication Critical patent/NI201200183A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a una combinación antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino y a su uso en el tratamiento de tumores sólidos avanzados.
NI201200183A 2010-06-18 2012-12-07 Una combinación antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino NI201200183A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305653A EP2397135A1 (en) 2010-06-18 2010-06-18 An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
EP10306256A EP2481404A1 (en) 2010-11-15 2010-11-15 An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative

Publications (1)

Publication Number Publication Date
NI201200183A true NI201200183A (es) 2013-05-13

Family

ID=45347705

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201200183A NI201200183A (es) 2010-06-18 2012-12-07 Una combinación antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino

Country Status (23)

Country Link
US (1) US20130122113A1 (es)
EP (1) EP2582369A1 (es)
JP (1) JP2013528644A (es)
KR (1) KR20130088753A (es)
CN (1) CN103140224A (es)
AR (1) AR082005A1 (es)
AU (1) AU2011266635A1 (es)
BR (1) BR112012031917A2 (es)
CA (1) CA2802974A1 (es)
CO (1) CO6650420A2 (es)
DO (1) DOP2012000305A (es)
EA (1) EA201291268A1 (es)
EC (1) ECSP12012343A (es)
MA (1) MA34380B1 (es)
MX (1) MX2012014732A (es)
NI (1) NI201200183A (es)
PE (1) PE20130312A1 (es)
PH (1) PH12012502483A1 (es)
SG (1) SG186376A1 (es)
TN (1) TN2012000552A1 (es)
TW (1) TW201206419A (es)
UY (1) UY33457A (es)
WO (1) WO2011158206A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109851593B (zh) * 2019-02-01 2021-04-16 沈阳药科大学 基于淋巴介导转运的甘油三酯前药及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
DE69931766T2 (de) 1998-04-03 2007-05-31 Ajinomoto Co., Inc. Antitumorale mittel
US20020183266A1 (en) 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
FR2945210B1 (fr) * 2009-05-07 2011-07-01 Sanofi Aventis Combinaison antitumorale comprenant l'ave8062 et le sorafenib

Also Published As

Publication number Publication date
EP2582369A1 (en) 2013-04-24
UY33457A (es) 2012-01-31
MA34380B1 (fr) 2013-07-03
DOP2012000305A (es) 2013-01-31
PH12012502483A1 (en) 2013-03-25
ECSP12012343A (es) 2012-12-28
KR20130088753A (ko) 2013-08-08
AU2011266635A1 (en) 2013-01-10
PE20130312A1 (es) 2013-03-26
CN103140224A (zh) 2013-06-05
TW201206419A (en) 2012-02-16
CO6650420A2 (es) 2013-04-15
EA201291268A1 (ru) 2013-04-30
AR082005A1 (es) 2012-11-07
SG186376A1 (en) 2013-01-30
CA2802974A1 (en) 2011-12-22
JP2013528644A (ja) 2013-07-11
US20130122113A1 (en) 2013-05-16
MX2012014732A (es) 2013-01-22
BR112012031917A2 (pt) 2017-11-28
TN2012000552A1 (en) 2014-04-01
WO2011158206A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
CY1123404T1 (el) Αντι-girt αντισωματα
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
EA201171367A1 (ru) Винилиндазолильные соединения
CL2015000829A1 (es) Inhibidores de histona desmetilasas
BR112015019432A2 (pt) Compostos de tubulisina, métodos de produção e uso
CU20120042A7 (es) (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
UY34342A (es) ?derivados de pirrolopirimidina y purina?.
AR089993A1 (es) Macrociclos peptidomimeticos
CL2012001405A1 (es) Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer.
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
EA201400178A1 (ru) Лечение рака молочной железы
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
CR20110553A (es) Terapia complementaria contra el cáncer
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
CL2013003577A1 (es) Uso de una composicion farmaceutica que comprende panobinostat y ruxolitinib en la prevencion y/o tratamiento de neoplasias mieloproliferativas.
MX2016008448A (es) Conjugados de var2csa-farmaco.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
DK2252322T3 (da) Vaccinesammensætninger
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.
CR20110573A (es) Combinacion antitumoral que comprende ave8062 y sorafenib